Nationally-Recognized Riverside Medical Center Selects Glytec as Part of its Ongoing Commitment to Clinical Excellence

Nationally-Recognized Riverside Medical Center Selects Glytec as Part of its Ongoing Commitment to Clinical Excellence

Hospital to leverage Glytec’s eGMS ®solution for advanced glycemic management decision support.

News Site:  Business Wire - Press Release
Date:  March 16, 2016

Waltham, MA — Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, announced today that Riverside Medical Center (RMC), has selected the company’s eGlycemic Management System® (eGMS®) to further strengthen its Diabetes Management Program. eGMS® enables providers, payers and patients to control glucose levels and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.

RMC, a nationally recognized, award-winning hospital with leading programs in cardiovascular, oncology, neurosurgery and orthopedics care, is a Magnet® Recognized hospital and has received Healthgrades Distinguished Hospital Award for Clinical Excellence™, and has also been named a Top 100 Hospital four years in a row. The hospital has a long-standing tradition of applying innovative, advanced technology in order to provide the best care possible for its patients.

“The prevalence of both hyperglycemia and hypoglycemia in hospitalized patients is increasing and is associated with higher mortality, increased cost of care, and longer lengths of stay,” said Michael Mutterer, Senior Vice President & CNO, RMC. “Insulin management and glycemic control are critical components of providing outstanding-quality care for a large percentage of patients, which is why we recently chose to partner with Glytec.”

Glytec’s eGMS® centers on clinician-developed, algorithm-based software (Glucommander TM) designed to consider insulin sensitivity and individualize dosing recommendations to address and prevent excursions through all aspects of insulin therapy – including intravenous (IV), IV to subcutaneous transition, subcutaneous dosing, and pediatric dosing recommendations.

“As the healthcare industry continues to move towards value-based care, Glytec is collaborating with healthcare providers across the country to establish a new standard of care in glycemic control and improve patient outcomes across the continuum of care,” said Melanie Mabrey, DNP, ACNP-BC, BC-ADM, CDTC, FAANP, vice president of clinical practice, Glytec. “RMC’s many accolades demonstrate that they too share a passion for the best care for patients possible and we look forward to the impact our relationship will have on their patients.”

The eGMS® will be integrated with RMC’s Epic electronic health record system to allow for a seamless, comprehensive approach to diabetes management. Through the standardization of processes and personalization of treatment, eGMS® has been proven to reduce infection rates, length-of-stay, readmissions and nursing time.

“Recognizing there are many different options and choices in healthcare delivery technologies, choosing the right partner for the most important and impactful outcomes is key,” said Cheri Rogers RN, MSN, QI Coordinator for Cardiovascular Services, RMC. “Glytec offers a proven e-glucose management system to enhance and deliver best practices in hyperglycemia management to our patients while providing the commitment, structure and expert support for a successful partnership.”

About Glytec

Founded in 2006, Glytec is a rapidly growing digital health company specializing in integrated inpatient and outpatient technologies for diabetes care, with the mission of improving medication management and glycemic control across the continuum. eGMS®, Glytec’s cloud-based glycemic management decision support system, enables providers, payers and patients to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The modular eGMS® centers on the Glucommander suite of FDA-cleared, complex proprietary dosing algorithms for IV, subcutaneous and pediatric dosing. The management of patients requiring insulin therapy is furthered by seamless EHR and connected device integration (SmartClick™), robust analytics (GlucoMetrics™) and surveillance (GlucoSurveillance™) capabilities. eGMS® interventional clinical decision support tools allow providers to standardize processes and personalize treatment across all areas of care, and is proven to result in significant improvements in clinical and financial outcomes versus traditional methods. For more information, please visit www.glytecsystems.com.

Request Demo